NasdaqGM - Nasdaq Real Time Price USD

Oculis Holding AG (OCS)

Compare
14.60 -0.29 (-1.95%)
At close: October 14 at 4:00 PM EDT
Loading Chart for OCS
DELL
  • Previous Close 14.89
  • Open 14.98
  • Bid 14.58 x 100
  • Ask 14.73 x 100
  • Day's Range 14.50 - 15.00
  • 52 Week Range 9.05 - 15.50
  • Volume 30,716
  • Avg. Volume 28,282
  • Market Cap (intraday) 609.481M
  • Beta (5Y Monthly) 0.09
  • PE Ratio (TTM) --
  • EPS (TTM) -1.63
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 28.79

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

oculis.com

36

Full Time Employees

December 31

Fiscal Year Ends

Recent News: OCS

View More

Performance Overview: OCS

Trailing total returns as of 10/14/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

OCS
30.01%
S&P 500
22.85%

1-Year Return

OCS
32.73%
S&P 500
35.40%

3-Year Return

OCS
48.68%
S&P 500
34.28%

5-Year Return

OCS
50.36%
S&P 500
41.96%

Compare To: OCS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: OCS

View More

Valuation Measures

Annual
As of 7/12/2024
  • Market Cap

    609.90M

  • Enterprise Value

    473.86M

  • Trailing P/E

    63.97

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    4.63

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -28.77%

  • Return on Equity (ttm)

    -58.12%

  • Revenue (ttm)

    871k

  • Net Income Avi to Common (ttm)

    -66.84M

  • Diluted EPS (ttm)

    -1.63

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    117.92M

  • Total Debt/Equity (mrq)

    1.19%

  • Levered Free Cash Flow (ttm)

    -25.16M

Research Analysis: OCS

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 245k
Earnings -20.84M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

20.05
28.79 Average
14.60 Current
37.09 High
 

Company Insights: OCS

People Also Watch